Best June Stock picks to own ..... (Public, NASDAQ:MNKD) , (Public, NYSE:TXT) ,(Public, NASDAQ:HDNG) .

1. Hardinge Inc. 

(Public, NASDAQ:HDNG) 9.37 a share / target price is 12.00 a share

Hardinge Inc. (Hardinge) is a designer, manufacturer and distributor of machine tools, specializing in precision computer numerically controlled metal-cutting machines. The Company supplies high precision computer controlled metal-cutting turning machines, grinding machines, vertical machining centers, and accessories related to those machines. The Company has manufacturing facilities located in Chemung County, New York; St. Gallen, Switzerland; Biel, Switzerland; Nan Tou City, Taiwan, and Shanghai, People's Republic of China. Canadian Hardinge Machine Tools, Ltd, Hardinge Technology Systems, Inc., Hardinge Holdings GmbH, Hardinge Holdings B.V., Hardinge GmbH, Hardinge Machine Tools, Ltd., Hardinge Machine Tools B.V., L. Kellenberger & Co. AG, Hardinge China, Limited, Hardinge Machine (Shanghai) Co., Ltd., Hardinge Taiwan Precision Machinery Limited, Hardinge Machine Tools B.V. and Taiwan Branch (Hardinge Taiwan). s the 2nd best-performing stock year-to-date in this segment of the market. It has risen 70.36% since the beginning of this year. Its price percentage change is 78.82% for the last 52 weeks.Large Move with Relatively Low Short Interest.Very cheap stock based on Fundamentals. Stock is profitable.Hardinge's products are used in the aerospace, energy, transportation, medical-equipment, automotive, and electronics industries.Very solid company that has been around for a long time. Well-placed company that is trading at a huge discount right now. Probably going to add a decent-sized position, "growth company at value prices with global reach"              Silly Bandz Rock Bandz - 24 Pack

2. 

Textron Inc. 

(Public, NYSE:TXT) 18.96 a share / target price 24.00 

Textron Inc. is a multi-industry company with a global network of aircraft, defense, industrial and finance businesses to provide customers with products and services worldwide. It conducts its business through five operating segments: Cessna, Bell, Textron Systems and Industrial, which represents its manufacturing businesses, and Finance, which represents its finance business. Cessna has five major lines of business: Citation business jets, Caravan single-engine utility turboprops, Cessna single-engine piston aircraft, aftermarket services and lift solutions by CitationAir. Textron Systems provides products to the defense, aerospace and general aviation markets. The Industrial segment includes its Kautex, Greenlee, E-Z-GO and Jacobsen businesses. Its Finance segment consists of Textron Financial Corporation (TFC) and its subsidiaries. In April 2009, the Company completed the sale of HR Textron, an operating unit within its Textron Systems segment, to Woodward Governor Company. When Textron (NYSE:TXT) reported earnings 43 days ago on April 22, 2010, analysts, on average, expected the company to report a loss of $0.01 on sales of $2.4 billion.
The company actually reported EPS of $0.05 on sales of $2.2 billion, beating EPS estimates by $0.06 and missing revenues estimates by $151 million.
Since the company's report, share of Textron have fallen from $24.23 to $18.96, representing a loss of 21.75% in the past 43 days.DEFENSE- DEFENSE- DEFENSE, Strong military contarcts, solid product profile.Great business. Should rebound.
 

3.

MannKind Corporation 

(Public, NASDAQ:MNKD)  5.47 a share / target price 8.50

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The Company’s lead product candidate, AFREZZA (insulin human) Inhalation Powder, is insulin that has completed Phase III clinical trials. AFREZZA utilizes its Technosphere formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, the Company loads recombinant human insulin onto the Technosphere particles, however, this technology is not limited to insulin delivery. In March 2009, the Company submitted a new drug application (NDA) to the United Stated Food and Drug Administration (FDA) for AFREZZA. In June 2009, it acquired a quantity of bulk insulin from Pfizer Manufacturing Frankfurt GmbH, a subsidiary of Pfizer Inc. released its most recent earnings statement about a month ago on Friday, April 30th. MannKind Corp. missed expectations with a loss of 40 cents per share---4 cents above the analyst consensus of 44 cents per share.

Now that investors have had plenty of time to assimilate the information and update their positions, it's time to take another look at MannKind Corp.MNKD vs. Its Industry Peers, Simply put, they will get FDA approval following their June meeting and sign a lucrative deal with a big pharma co.

Looking at MNKDcompared to a few of its industry peers, you can see that it is underperforming most of them. This may seem like a bad time for most buyers of MNKD , this is a great time to buy on it low and , make some $$ in the long term play ... FDA approval of Mankind's new insulin dosing technology will be paradigm shift for diabetes patients. The Dreamboat dosing system requires no needles, is very easy to use, uniquely fast acting (effective blood levels in 14 minutes), safe and effective. Multi-bagger stock potential within 1 yr. There is a large market for this product, and the drug will most likely be approved considering previous insulin inhalants were approved. I feel sure there will be a nice bump in price when the FDA approves.